Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Neoplasms, Second Primary 1Leukemia, Myeloid, Chronic-Phase 1Gastro Intestinal Stromal Tumor 1Congenital Abnormalities 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Sorafenib 20lenvatinib 18Hepatectomy 17Blood Specimen Collection 12Immune Checkpoint Inhibitors 11atezolizumab 9Liver Transplantation 9Surgical Procedures, Operative 7Radiofrequency Ablation 7Observation 7Bevacizumab 7regorafenib 5gadolinium ethoxybenzyl DTPA 5sintilimab 4donafenib 4camrelizumab 4Radiotherapy 4Magnetic Resonance Spectroscopy 4tislelizumab 3spartalizumab 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Mass Spectrometry 3Immunohistochemistry 3Doxorubicin 3Angiogenesis Inhibitors 3toripalimab 2pembrolizumab 2entecavir 2apatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma, Hepatocellular × Tyrosine Kinase Inhibitors × Clear all
NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

First Hospital of China Medical University

Active not recruiting
97 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡